Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists-Reference-Cited by-同舟云学术

Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists

Published:2023-02-02 Issue:4 Volume:66 Page:2918-2945
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Scott James S.¹^ORCID,Stead Darren¹,Barlaam Bernard¹^ORCID,Breed Jason²,Carbajo Rodrigo J.¹^ORCID,Chiarparin Elisabetta¹,Cureton Natalie¹,Davey Paul R. J.¹,Fisher David I.²,Gangl Eric T.³,Grebe Tyler³,Greenwood Ryan D.¹,Hande Sudhir³,Hatoum-Mokdad Holia³,Hughes Samantha J.¹,Hunt Thomas A.¹,Johnson Tony¹,Kavanagh Stefan L.⁴,Klinowska Teresa C. M.¹,Larner Carrie J. B.⁴^ORCID,Lawson Mandy¹,Lister Andrew S.¹,Longmire David¹,Marden Stacey⁵,McGuire Thomas M.¹,McMillan Caroline¹,McMurray Lindsay¹,Morrow Christopher J.¹,Nissink J. Willem M.¹^ORCID,Moss Thomas A.¹,O’Donovan Daniel H.¹^ORCID,Polanski Radoslaw²,Stokes Stephen¹,Thakur Kumar³,Trueman Dawn¹,Truman Caroline²,Tucker Michael J.¹,Wang Haixia³,Whalley Nicky¹,Wu Dedong⁵,Wu Ye³,Yang Bin³^ORCID,Yang Wenzhan⁵

Affiliation:

1. Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom

2. Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom

3. Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States

4. Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 OAA, United Kingdom

5. Advanced Drug Delivery, Pharmaceutical Sciences, R&D, Boston, Massachusetts 02451, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01964

Reference39 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Form and Function: how Estrogen and Progesterone Regulate the Mammary Epithelial Hierarchy

3. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.

4. National Cancer Institute. Hormone Therapy for Breast Cancer, 2020.

5. Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. X-ray crystallography study and optimization of novel benzothiophene analogs as potent selective estrogen receptor covalent antagonists (SERCAs) with improved potency and safety profiles;Bioorganic Chemistry;2023-12

2. Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity;Journal of Medicinal Chemistry;2023-08-30

3. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges;Journal of Medicinal Chemistry;2023-06-28

4. Discovery of a Potent and Orally Bioavailable Estrogen Receptor Degrader-Antagonists;Synfacts;2023-06-16

5. Selenium Analogue of LSZ102 as a Highly Potent ER‐α Binder;European Journal of Organic Chemistry;2023-06-14